Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (71-80 of 165) with videos related to

Pageof 17
Sort By:
European Journal of Immunology|September 26, 2017
NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHDYuen Ling Tracey Chan, Jianmin Zuo, Charlotte Inman, et al.
Haematologica|April 16, 2016
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemiaCharles Craddock, Myriam Labopin, Marie Robin, et al.
British Journal of Haematology|May 22, 2008
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasiaEleni Tholouli, Effie Liakopoulou, Hayley M Greenfield, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2018
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic SyndromesMarcos de Lima, Betul Oran, Richard E Champlin, et al.
Journal of Hematology & Oncology|September 4, 2016
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTFrancesco Saraceni, Myriam Labopin, Norbert-Claude Gorin, et al.
Blood Advances|March 3, 2019
Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cellsFrancesca A M Kinsella, Jianmin Zuo, Charlotte F Inman, et al.
British Journal of Haematology|February 12, 2026
Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practiceAleece MacPhail, Justin Loke, Brett L Houston, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan AllograftsKile Green, Kim Pearce, Rob S Sellar, et al.
The Lancet. Haematology|December 15, 2021
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trialMhairi Copland, Daniel Slade, Graham McIlroy, et al.
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.
Pageof 17

Showing results (71-80 of 165) with videos related to

Sort By:
Pageof 17
European Journal of Immunology|September 26, 2017
NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHDYuen Ling Tracey Chan, Jianmin Zuo, Charlotte Inman, et al.
Haematologica|April 16, 2016
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemiaCharles Craddock, Myriam Labopin, Marie Robin, et al.
British Journal of Haematology|May 22, 2008
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasiaEleni Tholouli, Effie Liakopoulou, Hayley M Greenfield, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2018
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic SyndromesMarcos de Lima, Betul Oran, Richard E Champlin, et al.
Journal of Hematology & Oncology|September 4, 2016
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTFrancesco Saraceni, Myriam Labopin, Norbert-Claude Gorin, et al.
Blood Advances|March 3, 2019
Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cellsFrancesca A M Kinsella, Jianmin Zuo, Charlotte F Inman, et al.
British Journal of Haematology|February 12, 2026
Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practiceAleece MacPhail, Justin Loke, Brett L Houston, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan AllograftsKile Green, Kim Pearce, Rob S Sellar, et al.
The Lancet. Haematology|December 15, 2021
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trialMhairi Copland, Daniel Slade, Graham McIlroy, et al.
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.
Pageof 17